Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Elizabeth Burtman

Pediatric Endocrinology Tenafly, NJ Medical Doctor

NPI 1679866255 CMS profile 1379557

2 Dean Dr Ste 2, Tenafly, NJ 07670

Open in the dashboard

General payments

$10,481

348 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Elizabeth Burtman of Tenafly, NJ is reported in the CMS Open Payments database as having received $10,481 across 348 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 82nd percentile of Pediatric Endocrinology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $983 58
2024 General $1,740 49
2023 General $4,865 69
2022 General $1,117 63
2021 General $866 46
2020 General $474 31
2019 General $437 32

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Elizabeth Burtman
  • Pediatric Endocrinology median
  • Middle half of Pediatric Endocrinology
  • National median

In program year 2025, general payments to Elizabeth Burtman were reported at $983. Among 971 Pediatric Endocrinology profiles paid that year, the median was $293 and the middle half received between $106 and $1,640.

Show as a table
Year Elizabeth Burtman Pediatric Endocrinology median Middle half National median
2019 $437 $196 $68–$845 $163
2020 $474 $124 $37–$722 $114
2021 $866 $134 $35–$691 $132
2022 $1,117 $177 $47–$726 $149
2023 $4,865 $236 $75–$887 $160
2024 $1,740 $259 $91–$979 $164
2025 $983 $293 $106–$1,640 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Pfizer Inc. $4,977 48 payments
  2. AbbVie, Inc. $1,576 84 payments
  3. Novo Nordisk Inc $1,331 76 payments
  4. Ascendis Pharma, Inc. $508 25 payments
  5. Amneal Pharmaceuticals LLC $306 22 payments
  6. Rhythm Pharmaceuticals, Inc. $183 11 payments
  7. Sandoz Inc. $163 11 payments
  8. TOLMAR Pharmaceuticals, Inc. $149 3 payments
  9. Endo Pharmaceuticals Inc. $135 10 payments
  10. Tolmar, Inc. $128 8 payments
  11. Other $1,025 50 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $6,005 338 payments
  2. Consulting Fee $3,060 1 payment
  3. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $740 1 payment
  4. Travel and Lodging $456 1 payment
  5. Education $120 6 payments
  6. Gift $100 1 payment
Products named General payments · program years 2019–2025
  1. NGENLA $3,973 12 payments
  2. LUPRON DEPOT $1,114 56 payments
  3. Sogroya $559 27 payments
  4. GENOTROPIN $553 37 payments
  5. SKYTROFA $508 25 payments
  6. Norditropin $483 36 payments
  7. SYNTHROID $314 20 payments
  8. UNITHROID $306 22 payments
  9. FENSOLVI $264 10 payments
  10. Imcivree $183 11 payments
  11. Other $1,899 95 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

348 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Pediatric Endocrinology in New Jersey

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record